CIGNA CORP Form 425 July 24, 2015

Anthem and Cigna: Combination Creates Premier Health Services Company 1 Filed by Anthem, Inc.

(Commission File No. 001-16751) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934
Subject Company: Cigna Corporation Commission File No. 001-08323



Safe Harbor Statement (1 of 2)

Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995:

This document, and oral statements made with respect to information contained in this communication, contain certain forward looking information about Anthem, Inc. ( Anthem ), Cigna Corporation ( Cigna ) and the combined businesses of Anthem a Cigna that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not generally historical facts. Words such a expect(s),

feel(s), believe(s), will, may, anticipate(s), intend, estimate, project and similar expressions (including the negative thereof) are intended to identify forward-looking statements, which generally are not historical in nature. These statements include, but are not limited to, statements regarding the merger between Anthem and Cigna; Anthem s financing of the proposed transaction; the combined company s expected future performance (including expected results of operations and financial guidance); the combined company s future financial condition, operating results, strategy and plans; statements about regulatory and other approvals; synergies from the proposed transaction; the combined company s expected debt-to-capital rai and ability to retain investment grade ratings; the closing date for the proposed transaction; financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain known and unknow risks and uncertainties, many of which are difficult

actual results and other future events to differ materially from those expressed in, or implied or projected by, the forward-looki information and statements. These risks and uncertainties include: those discussed and identified in Anthem s and Cigna s pu filings

with

predict and generally beyond Anthem s

and
Cigna s
control,
that
could
cause

the

U.S.

Securities

and

Exchange

Commission

(the SEC ); those relating to the proposed transaction, as detailed from

time to time in Anthem s and Cigna s filings with the SEC; increased government participation in, or regulation or taxation of health benefits and managed care operations, including, but not limited to, the impact of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, or Health Care Reform; trends in health care costs an utilization rates; our ability to secure sufficient premium rates including regulatory approval for and implementation of such rate our participation in the federal and state health insurance exchanges under Health Care Reform, which have experienced and continue to experience challenges due to implementation of initial and phased-in provisions of Health Care Reform, and which entail uncertainties associated with the mix and volume of business, particularly in Individual and Small Group markets, that could

negatively impact the adequacy of our premium rates and which may not be sufficiently offset by the risk apportionment provisions of Health Care Reform; our ability to contract with providers consistent with past practice; competitor pricing below market trends of increasing costs; reduced enrollment, as well as a negative change in our health care product mix; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon and funding risks with respect to revenue received from participation therein; our projected consolidated revenue growth and global medical customer growth; a downgrade in our financial strength ratings; litigation and investigations targeted at our industry and our ability to resolve litigation and investigations within estimates; medical malprac or professional liability claims or other risks related to health care services provided by our subsidiaries;

Safe Harbor Statement (2 of 2)

Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995 Continued:

our ability to repurchase shares of its common stock and pay dividends on its common stock due to the adequacy of its cash flow

and

earnings

and

other
considerations;
noncompliance
by
any
party
with
the
Express
Scripts,
Inc.
pharmacy

benefit

management services agreement, which could result in financial penalties; our inability to meet customer demands, and sanctions imposed by governmental entities, including the Centers for Medicare and Medicaid Services; events that result in negative publicity for us or the health benefits industry; failure to effectively maintain and modernize our information systems and e-business organization and to maintain good relationships with third party vendors for information system resources; even that may negatively affect Anthem s licenses with the Blue Cross and Blue Shield Association; possible impairment of the valuation our intangible assets if future results do not adequately support goodwill and other intangible assets; intense competition to attract and retain employees; unauthorized disclosure of member or employee sensitive or confidential information, including a impact and outcome of investigations, inquiries, claims and litigation related to the cyber attack Anthem reported in February 2015; changes in the economic and market conditions, as well as regulations that may negatively affect our investment portfolionand liquidity; possible restrictions in the payment of dividends by our subsidiaries and increases in required minimum levels of

capital and the potential negative effect from our substantial amount of outstanding indebtedness; general risks associated with mergers and acquisitions; various laws and provisions in Anthem's governing documents that may prevent or discourage takeovers and business combinations; future public health epidemics and catastrophes; and general economic downturns. Important factors that could cause actual results and other future events to differ materially from the forward-looking statemen made in this communication are set forth in other reports or documents that Anthem and/or Cigna may file from time to time with the SEC, and include, but are not limited to: (i) the ultimate outcome of the proposed transaction, including the ability to achieve the synergies and value creation contemplated by the proposed transaction, (ii) the ultimate outcome and results of integrating the operations of Anthem and Cigna, (iii) disruption from the merger making it more difficult to maintain businesses and operational relationships, (iv) the risk that unexpected costs will be incurred in connection with the proposed transaction,

the timing to consummate the proposed transaction, (vi) the possibility that the proposed transaction does not close, including,

but

not

limited

to,

due

to

the

failure

to

satisfy

the

closing

conditions,

including

the receipt of required regulatory approvals and

the receipt of approval of both Anthem s and Cigna s shareholders and stockholders, respectively, and (viii) the risks and uncertainties detailed by Cigna with respect to its business as described in its reports and documents filed with the SEC. All forward-looking statements attributable to Anthem, Cigna or any person acting on behalf of Anthem and/or Cigna are expressl qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by federal securities law, neither Anthem nor Cigna undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events or the receipt of new information. Readers are also urged to carefully review and consider the various disclosures in Anthem s and Cigna s SEC reports.



Non-GAAP Measures

Non-GAAP Measures:

This presentation includes certain non-GAAP financial measures. These non-GAAP measures may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation of, or as a substitute for, the financial information prepared and presented in accordance with GAAP. This data should be read in conjunction with previously published company reports on Forms 10-K, 10-Q and 8-K. We refer you to the

Appendix of these presentation materials for reconciliations to the most directly comparable GAAP financial measures and related information.

4



This communication does not constitute an offer to sell or a solicitation of an offer to sell or a solicitation of an offer to buy an securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such off solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities 1933, as amended, and otherwise in accordance with applicable law.

The proposed transaction between Anthem, Inc. ( Anthem ) and Cigna Corporation ( Cigna ) will be submitted to Anthem Cigna's shareholders and stockholders (as applicable) for their consideration. In connection with the transaction, Anthem and

will file relevant materials with the U.S. Securities and Exchange Commission (the SEC), including an Anthem registration on Form S-4 that will include a joint proxy statement of Anthem and Cigna that also constitutes a prospectus of Anthem, and e will

mail the definitive joint proxy statement/prospectus to its shareholders and stockholders, respectively. This communication is a substitute for the registration statement, joint proxy statement/prospectus or any other document that Anthem and/or Cigna may with the SEC in connection with the proposed transaction.

INVESTORS AND SECURITY HOLDERS OF ANTHEM AND CIGNA ARE URGED TO READ THE JOINT PROXY ST OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILAL IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to of the registration statement containing the joint proxy statement/prospectus and other documents filed with the SEC by Anthem Cigna (when available) through the web site maintained by the SEC at http://www.sec.gov. Copies of the documents filed with SEC by Anthem will be available free of charge on Anthem s internet website at http://www.antheminc.com or by contacting Investor Relations Department at (317) 488-6168. Copies of the documents filed with the SEC by Cigna will be available free on Cigna s internet website at http://www.cigna.com or by contacting Cigna s Investor Relations Department at (215) 761-41 Anthem, Cigna and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. You can find information about Anthem s executive officers and directors in Anthem s annual report on Form 10-K for the year ended December 31, 2014 and definitive

proxy

statement

filed

with

the

**SEC** 

on

April

1,

2015.

You

can

find

information

about

Cigna s

executive

officers

and

directors

in

Cigna s

annual

report

on

Form

10-K

for

the


year

ended December

31,
2014
and
its
definitive
proxy
statement
filed
with
the
SEC
on
March 13, 2015. Additional information regarding the interests of such potential participants will be included in the joint proxi
statement/prospectus
when
it
is
filed
with
the
SEC.
You
may
obtain
free
copies
of
these
documents
using
the
sources
indicated
above.
Important Information for Investors and
Shareholders
5

Participants
6
Joseph Swedish
Anthem President and Chief Executive Officer
David Cordani
Cigna President and Chief Executive Officer
Wayne DeVeydt

Anthem EVP and Chief Financial Officer Doug Simpson Anthem VP Investor Relations



**Transaction Summary** 

7

188.00 per share in the form of  ${\sim}55\%$  funded through cash and  ${\sim}45\%$  funded through Anthem stock

<sup>\*</sup> Calculated as of Anthem s and Cigna s closing stock price on May 28, 2015; stock consideration based on a fixed exchange

38.4%

premium to Cigna s unaffected stock price\*

Anthem shareholders to own ~67% and Cigna shareholders to own ~33% of the combined company

Cash portion financed through cash on hand and new debt issuance; equity portion through issuance of Anthem shares to Cigna shareholders

Pro forma debt-to-cap approximately 49% at closing projected to decline to low 40% two years post-close

Committed to retaining investment grade debt ratings

Shareholder vote required for both companies

Regulatory approvals including Hart-Scott-Rodino, state departments of insurance and other regulators

Anticipated closing in the second half of 2016

Expanded Footprint Enhances Ability to Compete

8

Source: Company Filings.

Note: Medical membership data as of 1Q 2015. Revenue projection based on the most recent 2015 outlook publicly reported by

38.5M

Combined Company Generates Over \$115 Billion in Annual Revenue Combined Company Generates Over \$115 Billion in Annual Revenue

Members 53.2M Members

Leading Position

Commercial Risk

Commercial ASO

Commercial 7100			
Government			
Individual			
Specialty			
International Leading Position			
Commercial Risk			
Commercial ASO			
Government			
Individual			
Specialty			
International Commercial- Risk 15% ASO 66% Medicare 4% Medicaid 11% FGS 3% International 1% Commercial- Risk 17% ASO 61% Medicare			

4%

Medicaid

14%

FGS

4%

Innovative Solutions Driving Affordability & Choice

Leadership position in advancing provider collaboration and new payment models

Proven health and wellness programs

Local focus advancing affordability

Technology centric investments across industry s largest base of membership

Enhanced administrative efficiency

Comprehensive product and funding offerings

Serving employer-sponsored, individual, state and federal government and international customers

Breadth of served segments addresses evolving needs of consumers over their lifetime

Diverse value based specialty products Affordability Choice

Combination of Complementary Businesses

Most recognizable brand

Local focus

A leading Commercial franchise

Strong Public Exchange execution

A leading and growing Medicaid franchise

A leading Medicare Supplement and improving Medicare Advantage business

Well-positioned for Dual Eligible opportunity Anthem

Strong Commercial player with broad geographic coverage

Middle Market ASO/Stop Loss solutions

A leading Specialty capability (Behavioral Health, Dental, Pharmacy, Disability & Life)

Proven wellness programs

Medicare position with leading physician-engagement model

Differentiated International businesses Diversified and Complementary Platforms 10 Cigna

Three Pillars to Benefit Combined Entity Provider Collaboration 11 Managing Total Cost of Care

Consumer Centricity Data and Insights Talent Affordability Quality Choice/ Personalization

Affordability Driven By Provider Collaboration and Connected Care 12 CUSTOMER Provider Collaboration Enhanced Personal

Health Care Program
Realized Outcomes
Select Models
Fewer acute inpatient
admissions
Decrease in outpatient
surgery costs
Fewer inpatient days per
1,000
Reduction in admission of
high risk patients
Reduction in ER visit costs
Decrease in ER utilization
PROVIDER
Both companies are aligned in their goals to

drive better health, choice and long-term affordability

Total Cost of Care Advantage 13 Demonstrated ability to drive medical cost savings for the nation's leading companies Company A

## 150,000+ members

6%+ in Year 1 savings Company B

200,000+ members

15%+ in Year 1 savings
Discounts alone do not capture the full value
Healthy
Healthy at Risk
Chronic
Acute
Broad and Proven Health, Wellness &
Engagement Capabilities Serving:

Consumer-centric Approach Caters to Member Needs

14

1

2

Choice &

Control

Ease &

Affordability

Feeling confident you are covered

and will be taken care of in the

event of a health issue

Understanding your costs and

coverage so there aren t any

negative surprises when you need

to use your benefits

Minimal interaction with your

insurer, except when you have a

question or an issue arises

then

high engagement through

personalized, effortless service

is demanded

Extensive research has identified the primary drivers of great consumer experiences

Confidence

in coverage

Clarity

in coverage

Ease

of getting help

Health &

Wellness Focus

3

Keys to a successful retail-oriented approach

Leading Data

Analytics

4

Compelling Financial Rationale 15 Synergies

Confidence in ability to capture run-rate synergies approaching \$2 billion

pre-tax within two years post-close

Expected PBM synergies have not been included in assumptions
Balance sheet

Committed to retaining investment grade debt ratings

Pro forma debt to cap of approximately 49% at closing with intent to decline to low 40% two years post-close

Expect to maintain our dividend

Will maintain flexibility with regards to share repurchases Adjusted EPS

Approaching 10% accretion to Adjusted Earnings per Share in first year post-close

Accretion more than doubles in year two

\* Transaction expected to close in the second half of 2016; 2018 estimate assumes transaction close on 12/31/2016 \$17.00+ Adjusted Earnings per Share in 2018\*

Identifiable and Achievable Synergies

Administrative structure

Operational efficiencies

Network efficiencies and medical management

Cross leverage best in class capabilities

Leverage Cigna Specialty capabilities across Anthem

Unique capabilities to serve growing Dual Eligible population

Potential PBM synergies have not been included
One-time implementation costs estimated to be ~\$600 million spread over two years
Precedent transactions comfortably affirm
a synergy level approaching \$2 billion
Confidence in
ability to achieve
annual synergies
approaching
\$2 billion
16

Value Creation for Both Sets of Shareholders

Adjusted Earnings per Share Greater than

+

- \* 2015 Adjusted EPS guidance excludes greater than \$0.25 per share of net unfavorable items. See appendix for the GAAP rec
- \*\* Transaction expected to close in the second half of 2016; 2018 estimate assumes transaction close on 12/31/2016

Strong growth from Medicaid, Individual / Exchange, Medicare Advantage, Dual Eligible, and Specialty

2018

Confidence in ability to achieve annual run-rate synergies approaching \$2 billion by year 2 + \$17.00+ Adjusted Earnings per Share in 2018\*\* 17 \$10.00 \$14.00 \$3.00 \$17.00 2015\*

A Clearly Defined Financing Plan (\$ in billions) Available cash \$6 Term loans and public debt \$22 Equity issued to

Cigna shareholders \$21 Total \$49 Financing considerations Anticipated financing sources

Received committed financing for the transaction

Permanent financing anticipated to include combination of term loans, public debt and equity portion of the merger consideration issued to Cigna shareholders

Debt-to-cap at close will be approximately 49%

Committed to de-levering and project to decline to low 40% debt-to-cap two years post-close

Committed to retaining investment grade debt ratings 18

Continues Anthem's and Cigna's Strong Track Records of Value Creation

Source: FactSet

data as of unaffected date of 5/28/15

Note: Share price performance over two years prior to unaffected date of 5/28/15

19

Anthem and Cigna Management teams have delivered on their promises

Both Management teams have an established track record of execution in this dynamic environment

Industry leading execution in several end markets

Anthem

109%

Cigna

97%

75%

100%

125%

150%

175%

200%

225%

250%

05/13

09/13

01/14

05/14

09/14

01/15

05/15

Anthem

Cigna

Successfully integrated and continue to outperform with Amerigroup and HealthSpring platform acquisitions

Compelling Transaction for Cigna Shareholders Unaffected Price on 5/28/15: \$135.87 Acquisition Price: \$188.00\* 10-day Trading Average as of 5/28/15: \$133.82 Median WS Target Price on 5/28/15: \$145.00 38.4%

Premium 40.5% Premium

Source: Bloomberg

Cigna shareholders to participate in significant upside of combined company

Approaching \$2 billion of annual run-rate synergies + potential upside from PBM optionality

Anthem s industry leading capital deployment track record Will participate in the significantly enhanced

value of the combined company

20

\* Calculated as of Anthem s closing stock price on May 28, 2015

\$80

\$100

\$120

\$140

\$160

05/14

07/14

09/14

10/14

12/14

02/15

03/15

05/15

Cigna

29.7%

Premium

21 Consideration Mix and Value Creation Given stock component, Cigna shareholders will share in the synergy value

Total consideration Cash consideration Stock consideration \$188.00 per share\* \$103.40 per share \$84.60 per share\*

<sup>\*</sup> Calculated as of Anthem s closing stock price on May 28, 2015

# Summary

22

Diverse well positioned global growth platform with over \$115 billion in combined annual revenue and 53 million medical members Enhances ability to advance health care access, affordability and quality for our customers

Meaningful opportunities to improve operational efficiency and

lower health care costs
Approaching 10% accretion to Adjusted EPS in year 1; more than doubling in year 2
Anthem and Cigna Boards unanimously support the transaction
Anthem and Cigna are highly confident in the ability to consummate the transaction
Anthem is committed to leading the change in health care delivery as a trusted partner for consumers

\*Estimated based on projections as of 7/24/15. Full Year 2015 Outlook\* Net income per diluted share Greater than \$9.75

net of related tax effects:

Net realized gains on investments

(\$0.33)

Other-than-temporary impairment losses on investments

\$0.08

Loss on extinguishment of debt

\$0.00

Amortization of other intangible assets

Greater

than \$0.50

Greater than \$0.25

Adjusted net income per diluted share

Greater than \$10.00

**GAAP** Reconciliation

24

We have referenced "Adjusted Net Income Per Diluted Share" (or Adjusted EPS), a non-GAAP measure, in this document. GAAP measure is intended to aid investors and analysts when comparing our financial results among periods. Management also this measure as a basis for evaluating performance, allocating resources, forecasting future operating periods and setting incent compensation targets. A reconciliation of this measure to the most directly comparable measure calculated in accordance with is presented below. For additional details, refer to our earnings results press releases and SEC filings, including but not limited Annual Report on Form 10-K for the year ended December 31, 2014, and our Quarterly Report on Form 10-Q for the three modeled March 31, 2015, available at www.antheminc.com.